- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
IDRS Labs seeks DCGI emergency nod for plant based drug against long COVID
A tripartite Memorandum of Agreement was signed among BARC, ACTREC-TMC and IDRS to develop Chlorophyllin against COVID-19 disease and other indications.
Bangalore: IDRS Labs Pvt Ltd, Bhabha Atomic Research Centre (BARC) and Advanced Centre for Treatment, Research and Education in Cancer - Tata Memorial Centre (ACTREC-TMC) have announced the completion of Phase II clinical trial of Sodium Copper Chlorophyllin 750 mg tablets.
The phase II clinical trial was a multi-center, randomized, open label, controlled trial of sodium-copper-chlorophyllin given along with treatment of physician's choice versus treatment of physician's choice in asymptomatic or mildly symptomatic patients with COVID-19.
A tripartite Memorandum of Agreement was signed among BARC, ACTREC-TMC and IDRS to develop Chlorophyllin against COVID-19 disease and other indications.
The dossier is filed for "Emergency Use Authorization (EUA)" for the treatment of SARS-CoV-2 Infection (COVID-19) by IDRS to Drug Controller General of India (DCGI) as stated by Mr. ShivkumarMadki, Co-founder & MD of IDRS Labs Pvt Ltd.
Read also: Jenburkt Pharma unveils FDC- Nervijen D3 in India
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751